Alireza Khodadadiyan

Alireza Khodadadiyan

Auto-generated profile, based on publicly available information

Alireza Khodadadiyan

Cardiovascular Research Center Shiraz University of Medical Sciences Shiraz Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Current Gastroenterology Reports
Verified
Journal Article
Closed access
PLParsa Lorestani
Parsa Lorestani
FFFerdos Faghihkhorasani
Ferdos Faghihkhorasani
HSHomina Saffar
Homina Saffar
BDBehnam Darabi
Behnam Darabi
YTYasaman Tavakoli
Yasaman Tavakoli
KJKimia Jazi
Kimia Jazi

1 January 2026 in Journal of Obesity
Verified
Journal Article
Open access
AKAlireza Khodadadiyan
Alireza Khodadadiyan
YKYalda Khazraei
Yalda Khazraei
MKMaliheh Kamali
Maliheh Kamali
KKKimiya Kolaei
Kimiya Kolaei
PAParmida Aminzadeh
Parmida Aminzadeh
AAAlireza Arzhangzadeh
Alireza Arzhangzadeh
Background: Orlistat is a potent lipase inhibitor utilized as a preventive agent for obesity and fat absorption control. Existing literature presents conflicting findings regarding its impact on lipid parameters. Methods: This systematic review followed the PRISMA guidelines and was registered in PROSPERO (ID: CRD42024550889). A comprehensive search of PubMed, Scopus, Web of Science, and Cochrane Register of Controlled Trials was conducted for studies published before January 19, 2025. Eligible studies included randomized controlled trials (RCTs) evaluating orlistat in adults (≥ 18 years) with dyslipidemia. Furthermore, the Grading of Recommendations, Assessment, Development, and Evaluations assessment tool was employed to analyze the certainty of evidence or each outcome. Results: A total number of 1369 participants, with 682 in treatment and 687 in control categories, were included in our study. Orlistat reduced body mass index (BMI) (SMD [95% CI]: −0.30 [‐0.58, −0.03], p value (heterogeneity) = 0.026), and also it was associated with a decrease in high‐density lipoprotein cholesterol (SMD (95% CI): −0.31 [‐0.48, −0.13], p value (heterogeneity) = 0.436). Changes in waist circumference (WC) and triglycerides (TGs) did not reach statistical significance in the primary analysis (WC: SMD [95% CI] −0.1562 [‐0.3138; 0.0015], I 2 = 0.0%, p ‐value (heterogeneity) = 0.7572; TG: SMD [95% CI] −0.1668 [‐0.7979; 0.4642], I 2 = 97.7% p value (heterogeneity) < 0.0001); however, after publication‐bias adjustment using the trim‐and‐fill sensitivity analysis, meaningful reductions were discovered for WC (SMD (%95CI): −0.1712 [‐0.3248; −0.0176], I 2 = 0.0%, p value (heterogeneity) = 0.7696) and TG (SMD (%95CI): −0.8900 [‐1.6619; −0.1181], I 2 = 97.9%, p value (heterogeneity) < 0.0001). The secondary analysis demonstrated that follow‐up duration accounted for 30% of TG heterogeneity, suggesting a small but significant decline in orlistat’s TG‐lowering effect over time (slope: −0.1239; 95% CI: −0.2355, −0.0123; p value = 0.0295). No significant changes were observed in other parameters of the study. Besides, gastrointestinal issues were the most frequently reported adverse events among the studies. Conclusion: Our findings suggest that orlistat meaningfully reduces BMI but is associated with decreased HDL‐C, which may be undesirable given HDL‐C’s protective role in cardiovascular health. Evidence for reductions in TG and WC is uncertain: the primary meta‐analysis showed no statistically significant effects, whereas trim‐and‐fill sensitivity analysis suggested potential reductions. No significant short‐term impact on TG was observed, though a modest reduction may emerge with prolonged use.

8 August 2025
Verified
Preprint
Open access
FSFeridoun Sabzi
Feridoun Sabzi
AAAsadollah Amiripour
Asadollah Amiripour
ARAmirmasoud Rahimi
Amirmasoud Rahimi
SNSeyed Hamid Nouri
Seyed Hamid Nouri
AKAlireza Khodadadiyan
Alireza Khodadadiyan

25 September 2026 in Clinical Cardiology
Verified
Journal Article
Open access
NKNasim Kheirandish
Nasim Kheirandish
MKMaliheh Kamali
Maliheh Kamali
AKAlireza Khodadadiyan
Alireza Khodadadiyan
HBHelia Bazroodi
Helia Bazroodi
MIMohammadhossein Imani
Mohammadhossein Imani
HDHamed Bazrafshan Drissi
Hamed Bazrafshan Drissi
Background: Coronary artery aneurysm (CAA), coronary artery ectasia (CAE), and coronary slow flow phenomenon (CSFP) are coronary pathologies associated with altered hemodynamics and increased thrombotic risk. However, optimal antithrombotic management remains uncertain because of limited and heterogeneous evidence. Objectives: This systematic review aimed to synthesize data on the efficacy and safety of antiplatelet and anticoagulant therapies in patients with CAA, CAE, and CSFP. Methods: Following PRISMA 2020 guidelines, PubMed, Scopus, Web of Science, and ProQuest were searched through September 2025 for randomized and observational studies evaluating antithrombotic therapy in adults with these conditions. Outcomes included major adverse cardiovascular events and major bleeding. Narrative synthesis was conducted using the SWiM framework. Risk of bias was assessed using ROBINS‐I and RoB 2.0, and certainty of evidence using GRADE. Results: Eleven studies comprising 3271 participants were included: six on CAE ( n = 895), four on CAA ( n = 2356), and one on CSFP ( n = 20). In CAE, dual antiplatelet therapy (DAPT) and oral anticoagulation (OAC) were associated with fewer ischemic events than no therapy, although direct comparisons were inconsistent. The only randomized trial in CAE showed numerically lower recurrent myocardial infarction and cardiovascular death with single antiplatelet therapy (SAPT) plus direct oral anticoagulant (DOAC) versus DAPT, but findings were nonsignificant and based on few events. Evidence for CAA and CSFP remains limited and inconclusive. Conclusions: Intensified antithrombotic therapy may benefit patients with CAE, but evidence remains inconclusive for CAA and CSFP. Large, multicenter randomized trials are warranted to establish condition‐specific treatment recommendations.

23 April 2025 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
PLParsa Lorestani
Parsa Lorestani
AKAlireza Khodadadiyan
Alireza Khodadadiyan
MKMohammad Amin Kaviari
Mohammad Amin Kaviari
AMAlireza Montazeri
Alireza Montazeri
HGHadi Golmoradi
Hadi Golmoradi
MTMohamad Reza Tohidi
Mohamad Reza Tohidi
Nocturnal enuresis represents a persistent pediatric health challenge characterized by variable treatment responses. Despite established therapeutic interventions, a substantial proportion of children fail to achieve successful management, highlighting the critical need for a deeper understanding of treatment resistance mechanisms. This study sought to systematically examine the multifaceted factors underlying differential treatment outcomes in childhood enuresis. A cross-sectional analytical study was conducted in 2017 at Mohammad Kermanshahi Hospital, Iran. The study included 144 children aged 5–8 years with nocturnal enuresis, divided into treatment-controlled (n = 85) and treatment-resistant (n = 59) groups. Participants received Desmopressin nasal spray (DDAVP) at 10 mcg/spray nightly. Demographics, clinical characteristics, sleep patterns, urination habits, and ultrasound findings were analyzed. The prevalence of controlled nocturnal enuresis was higher than treatment-resistant cases. Factors, including abnormal residual urine volume (P-value = 0.04), one episode of bedwetting per night (P-value = 0.03) and more than one episode of bedwetting per night (P-value = 0.02) were found to be statistically significant in our findings. Factors more common in the treatment-responsive group included deep sleep (85.9%), daytime urinary control (77.6%). Conversely, treatment-resistant children exhibited higher rates of poor medication adherence (94.9%), high urine volume per episode (86.4%), although these parameters were identified as non-statistically significant in our study. This study highlights critical factors differentiating treatment-resistant from treatment-responsive nocturnal enuresis in children. Key factors such as deep sleep, daytime urinary control, and effective fluid management were associated with controlled enuresis, while treatment-resistant cases were marked by poor adherence to medication, high urine volume per episode, and frequent enuresis. Future research should explore long-term efficacy and innovative approaches to enhance the management of nocturnal enuresis. Not applicable (This was a cross-sectional analytical study and did not involve a clinical trial).

20 September 2025
Verified
Preprint
Open access
YKYalda Khazraei
Yalda Khazraei
AKAlireza Khodadadiyan
Alireza Khodadadiyan
HBHamed Bazrafshan
Hamed Bazrafshan